创新药概念强势上扬 盘龙药业、中源协和等涨停

Group 1 - The innovative drug concept saw a strong rise on December 12, with companies like Sanwei Gene increasing over 12%, and others such as Jimin Health, Panlong Pharmaceutical, and Zhongyuan Qihe reaching the daily limit [1] - CICC pointed out that by 2025, domestic innovative drugs will produce internationally competitive clinical data, which will be published in major academic conferences or international medical journals, enhancing the valuation expectations for the innovative drug industry [1] - The market is expected to improve liquidity as the Federal Reserve enters a rate-cutting cycle starting in 2025, with domestic new drug clinical data exceeding expectations and significant licensing agreements being reached [1] Group 2 - The domestic CRO sector is currently under pressure due to low industry demand and declining order prices, impacting revenue growth and gross margins for companies [2] - It is anticipated that increased BD funding and secondary market activity will boost domestic new drug R&D demand and enhance financing activity for innovative drug projects, benefiting the domestic CRO sector [2] - A significant recovery in order volume is expected by 2026, with a focus on the domestic demand recovery and marginal changes in orders from leading CXO companies [2]